These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 36076571)

  • 1. PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications.
    Wang X; Zeng X; Li D; Zhu C; Guo X; Feng L; Yu Z
    Biomed Pharmacother; 2022 Sep; 153():113458. PubMed ID: 36076571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A Review.
    Guo MZ; Marrone KA; Spira A; Scott SC
    Cancer J; 2021 Nov-Dec 01; 27(6):476-481. PubMed ID: 34904810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.
    Nambiar DK; Mishra D; Singh RP
    Oncol Res; 2023; 31(4):405-421. PubMed ID: 37415740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
    Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in cancer therapy using PARP inhibitors.
    Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
    Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Highlights of PAPR Inhibitors in Small Cell Lung Cancer].
    Zhang S; Liu J; Yang C; Zhang L; Li S; Bao H; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):806-810. PubMed ID: 32752582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers.
    Lin C; Liu P; Shi C; Qiu L; Shang D; Lu Z; Tu Z; Liu H
    Fundam Clin Pharmacol; 2023 Apr; 37(2):194-214. PubMed ID: 36130021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations.
    Mgoboza C; Okunlola FO; Akawa OB; Aljoundi A; Soliman MES
    Cell Biochem Biophys; 2022 Sep; 80(3):495-504. PubMed ID: 35588345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibitors in gastric cancer: beacon of hope.
    Wang Y; Zheng K; Huang Y; Xiong H; Su J; Chen R; Zou Y
    J Exp Clin Cancer Res; 2021 Jun; 40(1):211. PubMed ID: 34167572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PARP inhibitors--theoretical basis and clinical application].
    Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
    Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
    Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status.
    Wu Y; Xu S; Cheng S; Yang J; Wang Y
    J Ovarian Res; 2023 Jan; 16(1):6. PubMed ID: 36611214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting DNA Damage Response Deficiency in Thoracic Cancers.
    Bzura A; Spicer JB; Dulloo S; Yap TA; Fennell DA
    Drugs; 2024 Sep; 84(9):1025-1033. PubMed ID: 39001941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.